Atrasentan 0.75 mg tablets contain the active ingredient Atrasentan, a selective endothelin-A (ETₐ) receptor antagonist used to reduce protein levels in the urine in adults with certain kidney diseases. It is primarily indicated for the treatment of primary immunoglobulin A nephropathy (IgAN) in patients at risk of rapid disease progression.

IgA nephropathy is a chronic kidney disease caused by abnormal immune deposits in the kidneys that lead to inflammation and progressive kidney damage. Atrasentan helps protect kidney function by blocking endothelin-mediated pathways that contribute to kidney injury and protein leakage into the urine.

Atrasentan helps reduce proteinuria (excess protein in urine), which is a key factor associated with worsening kidney function.

This medicine is prescribed by healthcare professionals and should only be used under medical supervision.

Primary Immunoglobulin A Nephropathy (IgAN).

Reduction of proteinuria in chronic kidney disease.

Slowing the progression of kidney damage in patients with IgA nephropathy (generally with a urine protein-to-creatinine ratio ≥1.5 g/g).

Patients receiving Atrasentan are typically those who have persistent proteinuria despite standard supportive therapy.

Lowering proteinuria helps slow the progression of kidney damage and may reduce the risk of kidney failure.

Atrasentan works by selectively blocking the endothelin type-A (ETₐ) receptor, which is involved in inflammation, fibrosis, and vasoconstriction in the kidneys.

By inhibiting this receptor, Atrasentan:

Reduces protein leakage into urine (proteinuria).

Decreases kidney inflammation.

Helps preserve kidney function.

Slows progression of chronic kidney disease associated with IgA nephropathy.

Clinical studies have demonstrated that the 0.75 mg dose significantly reduces albuminuria and improves certain cardiovascular risk markers.

The typical recommended dose is 0.75 mg once daily

General administration guidance:

Take the tablet orally as prescribed by your doctor.

Swallow the tablet whole with water.

Do not crush or chew the tablet.

Tablets may be taken with or without food.

Patients should follow their healthcare provider’s instructions carefully.

Common side effects may include:

Fluid retention or swelling (edema)

Decreased hemoglobin levels

Low blood pressure

Headache

Fatigue

Serious side effects may include:

Liver enzyme elevation

Severe fluid retention

Allergic reactions

Patients should contact their healthcare provider if severe symptoms occur.

Patients should inform their healthcare provider about all medications they are taking, including:

Prescription medicines.

Over-the-counter drugs.

Vitamins and herbal supplements.

Atrasentan is metabolized mainly through CYP3A enzymes, so drugs that strongly inhibit or induce CYP3A may affect its blood levels.

Store at 20°C–25°C (room temperature).

Keep tablets in the original container.

Protect from moisture and heat.

Keep out of reach of children.

Patients should undergo regular kidney function and blood tests during therapy.

Maintain follow-up appointments with your healthcare provider.

Do not stop taking the medicine without consulting your doctor.